The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics




The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics being added to The Veterans Affairs New VISTA S.O.A stratergy.

Scott Cragg, Special Assistant to the CIO, U.S. Department of Veterans Affairs and his Team.
John Teeter, Deputy Chief Information Officer, Department of Health and Human Services. CAPT Michael Weiner, Chief Medical Officer for the Defense Health Information Management System (DHIMS) Ed Meagher, Director, Strategic Healthcare Initiatives, SRA International; former Deputy Chief Information Officer, Dept. of Veterans Affairs (moderator) made their comments at the
AFFIRM The Association for Federal Information Resources Management ( http://affirm.org/ )May Monthly Luncheon on Health IT

The Department of Veterans affirs has a new System Called Veterans Health Information Systems and Technology Architecture (VISTA) said that they are not Including Genomics as a part of their VISTA system.

Genomics is the study of complex sets of genes, how they are expressed in cells (what their level of activity is), and the role they play in biology. Another way to think about it is as a small network of genes and how they work together to influence the a Veterans Breast CancerTumor's biology and behavior.

VISTA is built on a client-server architecture, which ties together workstations and personal computers with graphical user interfaces at Veterans Health Administration (VHA) facilities, as well as software developed by local medical facility staff. VISTA also includes the links that allow commercial off-the-shelf software and products to be used with existing and future
technologies. The Decision Support System (DSS) and other national databases that might be derived from locally generated data lie outside the scope of VISTA.

Hybrid Medical Analytics Our focus is on Genomic Trials. Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment. Unlike a genetic test, that provide information about a person's inherited genetic make-up. Instead,

Hybrid Medical Analytics looks at 21 genes in a patient's breast tumor trials to understand how these genes interact and influence the tumor's behavior.


Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems


Hybrid Medical Electronic e-Clinicals and early stage trials that allows
us unique insight into the most prevalent challenges at this phase of
testing. We have strategically built an infrastructure, methodology
and facility that meet those needs.